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There is no consensus as to the management of untreated poor prognosis or relapsed/refractory germ cell tumours. We have
studied an intensive cisplatin-based regimen that incorporates high-dose methotrexate (HD MTX) and actinomycin-D and etoposide
every 14 days (GAMEC). Sixty-two patients were enrolled in a phase 2 study including 27 who were untreated (IGCCCG, poor
prognosis) and 35 with progression despite conventional platinum based chemotherapy. The pharmacokinetics of the drugs were
correlated with standard outcome measures. Twenty of the untreated patients were progression free following GAMEC and
appropriate surgery, as were 18 individuals in the pretreated group. None of the established prognostic factors for therapy for
pretreated patients could identify a poor-prognosis group. Five out of nine late relapses to prior chemotherapy were progression free
following GAMEC and appropriate surgery. All patients had at least one episode of febrile neutropenia and there were five (8%)
treatment-related deaths. PK values were not predictive of efficacy or toxicity, although the dose intensity in the pretreated group of
patients, especially of HD MTX, was significantly correlated with progression-free survival (PFS). GAMEC is a novel intensive regimen
for this group of patients producing encouraging responses, although with significant toxicity. For those in whom it fails, further
therapy is still possible with durable responses being seen.
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The treatment of germ cell tumours (GCT) is one of the major
successes of cytotoxic chemotherapy, with the three-drug BEP
regimen (bleomycin, etoposide and cisplatin) being most estab-
lished. Four cycles of BEP are considered optimal for those with
untreated metastatic disease with the poorest prognosis in the
routinely used IGCCCG classification (International Germ Cell
Collaborative Group, 1997). For these individuals, the cure rate is
approximately 50%, and to date, no regimen in any randomised
controlled trial has shown a superior outcome (Kaye et al, 1998;
Hinton et al, 2003), although higher cure rates have been seen in
various phase II studies (Horwich et al, 2006).
Patients who relapse after first-line therapy have a durable cure
rate of between 25–60%, with the most significant prognostic
factors being the site of the primary, the response to initial
therapy, the duration of this response and the level of serum
tumour marker at relapse (McCaffrey et al, 1997). Cisplatin,
ifosfamide and a third drug (paclitaxel, etoposide or vinblastine)
are used most commonly with or without high-dose chemotherapy
consolidation (Rick et al, 2001; Kondagunta et al, 2005; Mead et al,
2005). Others have used a tandem or triple stem cell transplant
after initial stem cell mobilisation (Bhatia et al, 2000; Motzer et al,
2000).
On the basis of encouraging phase 2 data, several more complex
regimens have been utilised for untreated patients, and these have
generally intensified the drug cisplatin using a dose-dense
approach (including BOP/BEP (Anthoney et al, 2004), CBOP/BEP
(Christian et al, 2003)) or an approach in which additional agents
are added (such as POMB/ACE; Bower et al, 1997). In certain
patients, an etoposide dose of 500mgm
 2 is superior to
360mgm
 2 (Toner et al, 2001) (its absence from the initial few
weeks of the BOP/VIP-B regimen may account for the failure to
show an advantage of that treatment over BEP (bleomycin,
etoposide and cisplatin); Kaye et al, 1998).
In relapsed disease, we have found that a dose-dense cisplatin
using m-BOP (weekly cisplatin, MTX, bleomycin and vincristine),
led to long-term remissions in 42% of patients (Shamash et al,
1999). In addition, the combination of etoposide, actinomycin-D
and MTX (EAM) without cisplatin produced a complete remission
(CR) rate of 21% in patients who had relapsed after PVB (Levi
et al, 1990). This led us to develop granulocyte colony stimulating
factor, actinomycin-D, methotrexate, etoposide, cisplatin (GA-
MEC), which was designed to achieve dose-dense delivery of
cisplatin, early introduction of etoposide in a similar dose to
conventional BEP, the incorporation of sliding scale MTX at high
dose and add actinomycin-D to the therapy, with appropriate
colony factor support.
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efficacy endpoints have been documented for high-dose
methotrexate (HD MTX) in osteosarcoma (Crews et al,
2004) and acute lymphoblastic leukaemia (ALL), and for tenipo-
side in ALL (Evans et al, 1998). As this is a novel regimen,
PK studies on MTX, 7-hydroxy MTX (its metabolite implicated
in renal dysfunction), etoposide and actinomycin-D were
conducted to identify possible relationships between PK
parameters and either toxicity or efficacy. We also investigated
the overall survival, time to progression and toxicities using this
regimen.
PATIENTS AND METHODS
St Bartholomew’s Hospital, London is one of the largest referral
centres for GCT in the United Kingdom. Between September 1997
and June 2005, 62 patients were recruited for a phase 2 trial of
GAMEC chemotherapy, with appropriate ethical approval and
written informed consent. Twenty-seven were untreated patients
with poor prognosis disease using the IGCCCG criteria and 35 had
relapsed following at least one line of conventional platinum-based
therapy.
Relapse was defined as the appearance of new disease
or the development of increasing tumour markers in patients
with known sites of disease. Patients receiving first-line therapy
whose markers although not declining at the rate predicted
by their known half-lives, were nevertheless still falling,
were ineligible. Such patients completed their current therapy
and only became eligible if their markers started to
rise. Histological diagnosis was not mandatory in untreated
patients who had a testicular mass and elevated tumour markers,
if it were felt that delay of chemotherapy would compromise
survival; all patients were staged using whole-body CT before
therapy and all had renal function assessed using EDTA
glomerular filtration rate (GFR) clearances. The GAMEC schedule
is shown in Figure 1.
An induction cycle of baby BOP (cisplatin 50mgm
 2,
vincristine 2mg and bleomycin 30000U over 12h) was given to
patients who had renal obstruction, respiratory failure due
to disease, extensive inferior vena cava thrombosis thought to
be at high risk of pulmonary embolism and patients with
poor performance status (Eastern Co-operative Oncology Group
PS 3). In these individuals, GAMEC was given 10–14
days later with omission of cycle 1 day 8 cisplatin. Drug doses
were calculated on the basis of body surface area; the full dose
was deemed to be 100%, if a 20% dose reduction was needed then
the dose was said to be 80%. This percentage dose was multiplied
by the dose delivery (actual inter-cycle length divided by intended
inter-cycle length expressed as a percentage). The drugs were
analysed separately and then combined, assuming the contribution
of each drug to be equal.
At the end of therapy, patients underwent surgery to
remove sites of disease greater than 1cm in diameter (3cm in
seminoma). If any viable germ cell tumour elements were found,
no further therapy was given, unless the patient relapsed.
In patients with brain metastases, radiotherapy was not routinely
administered. Patients who progressed subsequently were
offered further chemotherapy with high-dose chemotherapy
consolidation.
Radiological assessment was carried out before week 6, unless
tumour markers showed a response. Treatment was not stopped if
tumour markers failed to decline at anticipated half-life. Tumour
markers including alpha foetoprotein (AFP) and human chorionic
gonadotrophin (bHCG) were routinely followed. In some patients,
the AFP rose during therapy, while the patient was responding due
to AFP production by the liver and additional scanning was used
to clarify this situation.
Pharmacokinetics
Twenty-four EDTA blood samples were collected over a 72h time
period from the start of treatment. Plasma was separated by
centrifugation (1200g for 10min) and stored at  401C until
analysis. Methotrexate, 7-hydroxymethotrexate (7-OH MTX) and
etoposide were detected by two separate HPLC methods with UV
detection. Actinomycin-D was measured by a novel LC-MS-MS
method with a sensitivity of o1ngml
 1 (Veal et al, 2005). PK
analysis was carried out in Kinetica (Innaphase Corp, Philadelphia,
PA, USA) using non-compartmental methods. Area under the
concentration–time curve (AUC) was determined by the trape-
zoidal method, using the linear rule for ascending concentrations
and the log linear rule for descending concentrations. Area under
the concentration–time curve was extrapolated to infinity by
dividing the concentration at 24h by the elimination rate constant
(lz), to derive AUC0–N. Total plasma clearance was derived from
the dose divided by AUC(0 N), or from steady-state concentration
at 12h (CSS) divided by the infusion rate (mgh
 1). Elimination
half-life (t1/2) was calculated as 0.693/lz.
Week 1 Week 2
Week 3
Day 1 2 3 4 567 891 01 11 21 31 41 5
Actinomycin 1 
mg m–2
Methotrexate dose 
(see below) 
Etoposide 90 
mg m–2
Cisplatin 50 mg m–2
Filgrastim 300 
mcg day–1 
Figure 1 GAMEC chemotherapy schedule. Week 1: actinomycin-D
(1mgm
 2) day 1: etoposide: 90mgm
 2, days 1–4 over 2h; MTX loading
dose over 30min followed by 12h infusion; day starting 4h after the
etoposide: cisplatin 50mgm
 2 over 4h days 3 and 4. MTX was given as
follows, depending on GFR: 4120mlmin
 1,2gm
 2 loading then 8gm
 2
over 12h (use 6gm
 2 over 12h if 430 years or PS41); 100–
119mlmin
 1,2 g m
 2 loading, then 6gm
 2 over 12h; 80–99mlmin
 1,
2gm
 2 loading, then 4gm
 2 over 12h; 60–79mlmin
 1,2gm
 2 loading,
then 3gm
 2 over 12h; 40–59mlmin
 1, 1.5gm
 2 loading followed by
2gm
 2 over 12h; 20–39mlmin
 1,1 g m
 2 loading only. Acetazolamide
was prescribed 500mg 2  per day for 3 days. Regular sodium bicarbonate
(100mmol), 6h with 20mmol KCl in 5% glucose for 48h. Folinic acid was
started 30h post-MTX treatment. Folinic acid: rescue commenced at 30h
post-MTX treatment. The first level of MTX was taken 24h post-infusion
start. Initial rescue was 100mg i.v. over 30min, followed by 250mg over
24h. If the 24-h level was o2mmoll
 1 continue with folinic acid 30mg, six
hourly for 3 days, otherwise give a further infusion of 350mg over 24h and
recheck level at 48h. If the 24h level 440mmoll
 1 the folinic acid was
increased to 700mg per 24h. At 48h and beyond: if the level were
43ml
 1 in the presence of renal impairment, the use of carboxypeptidase
was considered. If renal function was preserved, an infusion of 700mg per
24h was continued; if the level was 41 and o3mmoll
 1, 350mg was given
over 24h, and the level was checked every 24h. When the level was o1,
the dose was reduced to 30mg orally 4  per day, until the level was
o0.2ml
 1. Haematological parameters: filgrastim (300mcg per day) was
started on day 4 and continued until WBC43. To start each cycle, it was
necessary to have neutrophils41 10
9l
 1 and platelets460 10
9l
 1.
Renal parameters: U and E and creatinine (Cr) were measured daily, and if
Cr rose 420%, no cisplatin was given until Cr reduced below that level. If
the serum creatinine rose clearance by 15%, an EDTA clearance was
repeated. If the clearance was o40mlmin
 1, carboplatin AUC 4 was
substituted for cisplatin. In this case, vincristine was given on weeks 2, 4, 7
and 9. If the clearance subsequently improved, then cisplatin was
reintroduced and vincristine was dropped. Dose reductions: a 20% dose
reduction was made in the doses of cisplatin, actinomycin-D and etoposide,
in the presence of plateletso20 10
9l
 1 or neutrophilso0.5 10
9l
 1
for45 days. A 20% reduction in the dose of MTX was made in the
presence of grade 3 or 4 mucositis. A 50% dose reduction in the dose of
MTX was made, if the 24-h level was 480ml
 1 or the 48h level was
44ml
 1.
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sStatistical methods
Statistical analyses were performed with the STATA 8.2 statistical
software package. Overall survival (OS) and PFS were assessed
using the Cox proportional hazard method for continuous
variables. Survival curves were generated using the Kaplan–Meier
method. Categorical variables were analysed using the log-rank
test. To assess the correlation between the various categorical
variables and being progression free (PF) to GAMEC, Fisher’s
exact test was used. The median test was used to examine
continuous variables against PF status. Logistic regression was
used to determine which factors were predictive of being PF. PK
between group comparisons were made using the Mann–Whitney
U-test. Progression-free and overall survivals were analysed on an
intention to treat basis.
RESULTS
The majority of patients had non-seminomatous GCT and the
median age measured was 33 years (Table 1). At a median follow-
up of 2.5 years, 20 (74%) untreated patients were PF following
GAMEC and appropriate surgery (Table 2; Figure 2). There were
two treatment-related deaths (TRDs), one additional patient was
salvaged by further therapy (78% overall). Out of five patients with
central nervous system metastases at presentation, three remain
PF.
Eighteen (51%) of the pretreated group were similarly PF and a
further four were salvaged by additional therapy (63% overall).
There were three TRDs. Nine pretreated patients had late relapses
before GAMEC and five remain PF. Three patients had brain
metastases on relapse, two had post-chemotherapy surgery
confirming CR and that they were PF and one progressed and
died. Eight patients had viable cancer at surgery, five of them had
Table 1 Patient characteristics
Pretreated patients Untreated patients
(35) (27)
Median age (range) 24.6 (17.8–53.2) 31.1 (16–42.6)
Histology
Non-seminoma 26 17
Seminoma 7 0
Mixed 1 1
Unknown 1 9
Initial IGCCCG
Good 20 N/A
Intermediate 8 N/A
Poor 7 27
Orchidectomy
Yes 24 9
No 11 18
Outcome to prev chemo
CR 8 —
M ve PR 21 —
M+ve PR 4 —
PD 2 —
No prev therapies
12 9 0
26 0
HCG at start of GAMEC
Median 1693 (1–106000) 112559 (0–335000)
AFP at start of GAME
Median 38 (3–11352) 1427.5 (3–43500)
LDH at start of GAMEC
Median 480 (260–3880) 1123 (451–3661)
Raised 14 (median 1 normal) 25 (median 2.3 normal)
Dx sites at start of GAMEC
Lung 21 24
LNs 27 23
Liver 3 9
CNS 4 5
Other 8 (see 2 below) 14 (see 3 below)
Abbreviations: AFP, alpha foetoprotein; CR, complete remission; HCG, human
chorionic gonadotrophin; LDH, lactate dehydrogenase; M ve PR, marker-negative
partial response; M+ve PR, marker-positive partial response; N/A, not applicable.
Peritoneum, scrotum, testes, mediastinum, bone, inferior vena cava; Renal, bone,
spleen, adrenal, stomach, pericardium, testes, kidney, pleural effusion, skin, ascites,
intestine, ivc.
Table 2 Outcome to GAMEC
Pretreated
patients
Untreated
patients
35 27
Median number cycles 4 (range 2–5) 5 (range 1–5)
Baby BOP induction 2 10
Response to GAMEC Number PF Number PF
CR 3 3 3 2
SCCR 10 10 12 12
SICR (good) 3 3 0 0
SICR (poor) 5 0 0 0
M ve PR 6 2 9 6
M+ve PR 2 0 1 0
M ve SD 1 0 0 0
SD 1 0 0 0
PD 1 0 0 0
TRD 3 0 2 0
Total PF to
GAMEC+surgery
18
(51%)
20
(74%)
PF to other therapy 4 (11%) 1 (4%)
Total PF 22
(63%)
21
(78%)
Abbreviations: CR, complete remission; M ve PR, normalisation of tumour markers
with residual masses; M+ve PR, at least 90% reduction in markers for at least 1
month; PD, progressive disease; PF, progression free; SCCR, surgically confirmed CR;
SD, stable disease; SICR, surgically induced CR (viable cancer found at surgery, but all
sites of disease removed); TRD, treatment-related death. o5% viable cancer¼good;
45% viable cancer¼poor.
Untreated patients (N=27)
Pre-treated patients (N=35)
0.00
0.25
0.50
0.75
1.00
P
r
o
p
o
r
t
i
o
n
a
l
 
s
u
r
v
i
v
a
l
0 6 12 18 24 30 36 42 48 54 60
Months
Overall survival by group
Figure 2 Overall survival.
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sgreater than 10% viable tumour and all five relapsed. The
remaining three with less than 10% viable tumour were all PF.
High-dose chemotherapy was offered to 10 patients. In the
untreated group, four received high-dose therapy, but it was
unsuccessful in all of them. One received high-dose carboplatin
AUC20 with etoposide 1600mgm
 2 and cyclophosphamide
6gm
 2 Another patient received high-dose carboplatin AUC20
with thiotepa 500mgm
 2 and cyclophosphamide 6gm
 2. A third
patient received carboplatin AUC10 with irinotecan 200mgm
 2
and gemcitabine 360mgm
 2 over 72h, supported by autologous
stem cells and repeated and given sequentially three times. The
fourth patient received high-dose carboplatin AUC20 with etopo-
side 1600mgm
 2 and melphalan 140mgm
 2. In the pretreated
group, high-dose therapy consisted of high-dose carboplatin
AUC20 with etoposide 1600mgm
 2 and cyclophosphamide
6gm
 2 in two patients and was successful in one. High-dose
carboplatin AUC30 and etoposide 1600mgm
 2 was offered to one
patient, it but resulted in a TRD. High-dose topotecan 30mgm
 2,
carboplatin AUC21 and thiotepa 500mgm
 2 was offered to three
patients as part of a clinical trial, and it was successful in two.
Toxicity
The most common toxicities were myelosuppression and muco-
sitis (Table 3a). There were five TRDs (8%); four of these were due
to sepsis and one was due to intra-abdominal haemorrhage from
choriocarcinoma. A large number of cycles were complicated by
febrile neutropenia, with about half of them requiring platelet
transfusion (Table 3b).
Significant reversible renal dysfunction occurred in five of the
untreated patients (grade 2 WHO criteria), of whom one was
dialysed for 24h following an episode of septic shock. His renal
function before this had been normal and returned subsequently to
normal. In the pretreated group, four were similarly affected, one
of whom (who had significant renal problems with BEP) became
dialysis dependent long term. A total of 6% of cycles required the
omission of cisplatin, and in one-third of these cycles carboplatin
was substituted. One patient required carboxypeptidase to
inactivate MTX during the first cycle of treatment; his EDTA
clearance before HD MTX had been normal and he did not receive
any cisplatin on that cycle. Methotrexate was cautiously reintro-
duced on the third cycle without adverse effects after his renal
impairment had subsided.
Two patients developed typhlitis, one required a defunctioning
colosostomy that was subsequently reversed. Three patients
developed thrombo-embolic disease (all central access line
associated). Two patients required parenteral feeding. One patient
developed transient occipital blindness, he had received two lines
of prior cisplatin-based therapy. An MRI scan confirmed white-
matter changes in the occipital lobe, thought to be due to cisplatin
and not metastases. His vision subsequently recovered without
further therapy.
Prognostic factors
We looked at the following prognostic factors to see if they
correlated with PF status. They were age, presence of non-
seminomatous histology, raised lactate dehydrogenase (LDH),
Memorial Sloan-Kettering Cancer Center (MSKCC) criteria and
Medical Research Council (MRC) UK criteria for relapsed GCT
outcome. Only age (omedian age vs 4median age: 72 vs 29%, FET
(Fisher’s exact test)¼0.018) and raised LDH before GAMEC
(normal LDH vs raised LDH: 67 vs 29%, FET¼0.041) were
significant. In the pretreated group, neither the MRC criteria for
adverse outcome (bHCG or aFP 4100, failure to achieve a CR to
initial chemotherapy, relapse within 2 years) (Fossa et al, 1999) nor
those developed by MSKCC (Motzer et al, 2000), including
extragonadal primary, failure to achieve at least marker-negative
partial response (m ve PR), failure of two lines of cisplatin-based
therapy), were able to define a poor-prognosis group. The good-
risk group defined by the MSKCC (gonadal primary, one line of
cisplatin-based therapy, achievement of at least m vePR) (7/14
PF) and relapse at least 6 months from the end of the last
Table 3a Percentage of patients having grade 3/4 WHO toxicities
Pretreated Untreated
Cycle 1 2 3 4 5 1 2 3 4 5
Number of patients 35 35 29 21 17 27 26 26 24 18
Alopoecia 35 91 96 100 95 27 96 100 100 100
Anorexia 6 18 7 5 11 12 16 21 24 31
Diarrhoea 9 6 11 0 5 12 0 4 5 8
Constipation 0 0 4 0000 0 0 0
Infection 59 68 70 43 37 69 44 54 57 46
Lethargy 24 41 52 40 31 23 28 38 33 23
Mucositis 27 29 41 10 16 15 28 33 38 8
Nausea and vomiting 3 9 4 0044 8 0 8
Neuropathy 0 6 0 15 11 0 0 0 0 0
Neutropenia 91 93 85 95 61 93 93 83 80 67
Thrombocytopenia 82 96 89 95 78 85 96 67 90 93
Table 3b Blood product requirements
Pts requiring platelets Pts requiring blood transfusion
N % Med. % Med.
Pretreated patients
Cycle 1 35 37 1 37 3
Cycle 2 35 54 2 66 3
Cycle 3 29 59 2 69 3
Cycle 4 21 43 3 71 3
Cycle 5 17 41 2 59 3
Untreated patients
Cycle 1 27 22 3 44 6
Cycle 2 26 31 1.5 38 4.5
Cycle 3 26 50 1 58 3
Cycle 4 24 46 1‘ 62 3
Cycle 5 18 39 1 50 3
Abbreviation: Pts, patients.
LDH normal (N=21)
LDH raised (N=14)
P=0.013
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Figure 3 PFS in pretreated patients by absence or presence of raised
LDH.
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schemotherapy, also failed to define a group with a better prognosis
(8/12 PF). Only age and raised LDH were significant on
multivariate analysis (Figures 3, 4 and 5).
Dose delivery and outcome
In the untreated group, no relationship between dose delivered or
dose density was seen. In the pretreated group, when the two
components of dose density were entered as separate variables into
a regression model, both dose and inter-cycle delay were found to
be independently associated with PFS (Figure 6). The ideal (100%
dose) for MTX was adjusted for renal function, as shown in
Figure 1. The number of patients maintaining the dose of MTX at
X80% over the first 2 cycles was also significant; no other drug
alone showed a significant effect. However, for the four drugs
together, the overall dose density delivered was highly significant
(Table 4). Beyond the first two cycles, the effect of dose density was
no longer statistically significant for PFS.
Pharmacokinetics and pharmacodynamics
Pharmacokinetic data was obtained on 43 patients for MTX and
etoposide, and 31 patients for actinomycin-D. Summary data are
presented in Table 5. There was no relationship between renal
function (serum creatinine) and plasma clearance of MTX,
actinomycin-D or etoposide (r
2o0.1), although only seven patients
had serum creatinine values above the normal range
(4115mmoll
 1), and all were o139mmoll
 1.
The main aim of the pharmacological aspect of the study was to
identify relationships between pharmacokinetic parameters and
pharmacodynamic effects. The primary pharmacodynamic mea-
sures were PF status for efficacy, and neutrophils o0.5 10
9/l, for
o4days or X4 days for toxicity. AUC0 N was taken as the
primary PK measure. methotrexate, actinomycin-D or etoposide
AUC were not significantly predictive of efficacy or toxicity
(P40.1 throughout), nor was MTX CSS at 12h. 7-Hydroxymetho-
trexate AUC0 N was not predictive of renal toxicity, as indicated
by a 430% increase in serum creatinine (9317518 vs
7617468mgml
 1h
 1 in patients with and without renal toxicity,
respectively, P40.1).
As an overall measure of total cytotoxic exposure, the AUC
values for each drug were normalised (AUC/mean AUC) and
summed up. These values were also not predictive of efficacy
(1.970.3 vs 2.070.7, P40.1) or toxicity (1.970.7 vs 2.070.4, P40.1)
for MTXþetoposide or for MTXþetoposide þactinomycin-D
(2.970.4 vs 3.071.2 and 2.871.1 vs 2.870.6, respectively, P40.1).
Grouping patients according to individual PK values being greater
or less than the median values suggested an increased likelihood
of treatment failure in patients with MTX AUC values omedian
(13/21 vs 7/22, P¼0.048).
DISCUSSION
We show that the novel regimen GAMEC, with appropriate
surgery, produces a PFS of 74% in untreated patients and 51% in
previously treated patients. These data suggest this treatment to be
highly active in GCT. The permissive entry criteria allowing
patients without formal histology to enter the study meant that
very ill patients could be treated using this protocol. In addition,
the use of an induction cycle of baby BOP allowed these patients to
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Figure 4 PFS in pretreated patients by age (above and below median).
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Figure 5 PFS by Memorial Sloan-Kettering Risk Group.
80% (N=20)
<80% (N=14)
PFS in pre-treated patients by dose density over cycles 1–2
P=0.003
0.00
0.25
0.50
0.75
1.00
P
r
o
p
o
r
t
i
o
n
 
p
r
o
g
r
e
s
s
i
o
n
 
f
r
e
e
0 6 12 18 24 30 36 42 48 54 60
Months
Figure 6 PFS in pretreated patients by dose density over cycles 1 and 2.
Table 4 Pretreated patients: drug density and PF status to GAMEC
Pretreated Pts: drug density and PF to GAMEC
Cycles 1–2
% dose density o80% X80% P (FET)
Actinomycin 5/12 (42%) 13/22 (59%) 0.48
Methotrexate 1/9 (11%) 17/25 (68%) 0.006
Etoposide 4/12 (33%) 14/22 (64%) 0.15
Cisplatin 8 /18 (44%) 10/16 (62%) 0.33
Combined 3/14 (21%) 15/20 (75%) 0.004
Abbreviations: FET, Fisher’s exact test; PF, progression free; Pts, patients.
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sbe stabilised before commencing intensive therapy, and the use of
HD MTX here negated the requirement for cranial irradiation.
Many studies for intensive protocols in untreated GCT have
employed large doses of bleomycin, making them unsuitable for
salvage treatment. This regimen did not include bleomycin.
Concerns that this might compromise outcome could be off-set
by the fact that actinomycin-D produces a response rate of 38%,
which is greater than that of bleomycin (Early and Albert, 1976).
The regimen was accompanied by significant toxicity, with five
TRDs. These patients were older and one had only recently been
exubated following a laparotomy, and was severely malnourished.
There was a high frequency of mucositis and febrile neutro-
penia. Many cycles required the use of platelets, particularly if the
patients had been pretreated (Table 3b). It proved difficult to
deliver the treatment in older patients (435 years), and this was
the probable reason for their inferior survival. Nevertheless, for
those who relapsed, it was possible to give further therapy to all of
the patients in the untreated group and to the vast majority (16/17)
of the pretreated group. Adequate stem cell collections were also
possible in 9/11 patients in whom it were attempted, suggesting
that deferring high-dose chemotherapy for patients who relapsed
after GAMEC was practical.
We have shown that it is possible to deliver HD MTX in
combination with cisplatin (cisplatin given 38h after HD MTX).
The measurement of the serum creatinine 24h post-MTX allowed
identification of patients who had developed renal impairment,
and future chemotherapy could be dosed accordingly. The results
of the pharmacokinetic studies lead to the conclusion that 7-OH
MTX is not the cause of MTX-induced renal dysfunction, as has
been widely held to be the case. In these patients, cisplatin was
withheld until the serum creatinine fell, with levels checked every
12h. The role of MTX in relapsed disease remains controversial,
while single-agent data have proved to be disappointing. However,
regimens incorporating MTX have proved to be encouraging. Two
other intensive regimens have used MTX in intermediate doses
(BOMP/EPI (Germa-Lluch et al, 1999) and POMB/ACE (Husband
and Green, 1992)). Both used alkylating agents, although the dose
in POMB/ACE was low. The single-agent data in relapsed disease
used 1gm
 2 (Atkinson et al, 1987), substantially lower than that
used here.
The median delivery of cisplatin was 250mgm
 2 in the
pretreated and 270mgm
 2 in the untreated patients, suggesting
the targeted delivery of 300mgm
 2 to be realistic. The relationship
between dose density and outcome could only be found in the
pretreated group. It appeared that maintenance of dose density
over the first two cycles was the most important factor, with dose
intensity and absence of dose delay being equally important. The
failure to see such a relationship in the untreated group probably
reflects the low number of relapses in this group in the first place,
and this is similar to the finding with POMB/ACE chemotherapy
(Husband and Green, 1992). The failure of double-dose cisplatin in
BEP to improve survival in untreated patients questions the
wisdom of sole escalation of cisplatin as a major strategy to
improve outcome (Nichols et al, 1991).
For relapsed patients, the data presented are comparable to that
from other groups using high-dose therapy (Bhatia et al, 2000;
Motzer et al, 2000). Other groups have reported encouraging
results using alternative agents, for instance cisplatin and
epirubicin (Bedano et al, 2005), and recently an interesting case
report suggested that antiangiogenic agents may also have a role
(Voigt et al, 2006).
We failed to detect a significant difference in the outcome of
these patients, when the two most commonly used scoring systems
for prognosis (MRC (Fossa et al, 1999) and MSKCC (McCaffrey
et al, 1997)) were applied. It appears that the good group (using
the MSKCC criteria), for whom it has been suggested that the
cisplatin, ifosfamide and paclitaxel (TIP)-based approach is
frequently curative, fare as well as those reported (67% with
GAMEC vs 65%) (Kondagunta et al, 2005). Results from the poor-
risk relapse group, for whom conventional therapy seems
inadequate, appear as good as those reported for ifosfamide/
paclitaxel induction followed by three cycles of high-dose
carboplatin and etoposide treatment, supported by autologous
blood stem cells (50% with GAMEC vs 41%) (Motzer et al, 2000).
We could only identify two prognostic factors that correlated
with poor outcome, namely age and raised LDH before GAMEC. It
might have been that these simply were the patients who received a
lower intensity of therapy. In fact all of the six patients with raised
LDH who received o80% dose density over the first two cycles,
relapsed vs four of eight of those who received the higher dose
intensity. A similar finding existed for age (2/10 vs 3/6). Although
not statistically significant, there is a suggestion that adequate dose
intensity may overcome these adverse prognostic factors.
Late relapses appear salvageable with GAMEC (5/9), a group
thought to be chemorefractory. Recently, a similar finding has
been described with TIP (7/14) (Ronnen et al, 2005). Derived PK
values for MTX, actinomycin-D and etoposide clearance were
inline with previously published values (Clark et al, 1994; Crews
et al, 2004; Veal et al, 2005). These were not predictive of outcome.
The use of multiple drugs was a confounding factor, especially as
cisplatin pharmacokinetics were not assessed. The use of filgrastim
and folinate will have reduced the impact of pharmacokinetic
variability on myelosupression. Despite these caveats, there was a
trend towards lower MTX AUC in patients who relapsed.
Overall, these results show that GAMEC is an effective therapy
both for untreated patients and those who relapse. Further relapses
can still receive treatment thereafter. The data suggest that the
current prognostic scoring systems for relapsed patients fail to
identify a poor-prognosis group for this regimen. These encoura-
ging results have been obtained with established agents.
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Table 5 Pharmacokinetic data on MTX, 7-OH MTX, actinomycin-D and etoposide
AUC0–N (mgml
 1h
 1) CL (mlmin
 1m
 2) Half-life (h)
Methotrexate 273071444 72740 (from AUC) 4.671.4
94758 (from CSS)
7-OH methotrexate 8557439 — 13.276.0
Actinomycin-D 0.11070.077 190784 19.379.5
Etoposide 93724 16.374.8 6.772.1
Abbreviation: AUC, area under the concentration–time curve; MTX, methotrexate.
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